Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device company C.R. Bard (NYSE:BCR) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at C.R. Bard and see what CAPS investors are saying about the stock right now.

C.R. Bard facts



Headquarters (founded)

Murray Hill, N.J. (1907)

Market Cap

$8.1 billion


Healthcare equipment

Trailing-12-Month Revenue

$3.0 billion


Chairman/CEO Timothy Ring

President/COO John Weiland

Return on Equity (average, past 3 years)



$896.3 million / $1.4 billion

Dividend Yield



Boston Scientific

Johnson & Johnson 

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 279 members who have rated C.R. Bard believe the stock will outperform the S&P 500 going forward.

Earlier this week, one of those Fools, All-Star JohnCLeven, succinctly summed up the C.R. Bard bull case for our community:

[C.R. Bard] has been on my radar for a while. [C.R. Bard] exhibits many of the characteristics that I find appealing in a business including: high returns on capital and equity, consistent growth in earnings and free cash flows, share buybacks, and a solid balance sheet.

[C.R. Bard] has a solid position within the medical device industry, and I believe that probability is very high that [C.R. Bard] will continue to create significant value over the next 5-10 years, and probably much longer. At today's 6.8% free cash flow yield, this high-quality business should outperform in the long run.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.